GLAXOSMITHKLINE PLC Form 6-K July 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 16 July 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDM	R/person c	losely assoc	iated with t	them ('PCA')
----	----------------	------------	--------------	--------------	--------------

Ms E Walmsley a) Name

b) Position/status

Chief Executive Officer

Initial notification/

Initial notification

amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

each ('Ordinary Shares') ISIN: GB0009252882

Acquisition of Ordinary Shares following the

re-investment of dividends b) Nature of the transaction

paid to shareholders on 12

July 2018.

Price(s) Volume(s) c) Price(s) and volume(s) £15.7091 1450.373

n/a (single transaction)

Aggregated information

Aggregated volume Price

e) Date of the transaction 2018-07-12

Place of the transaction London Stock Exchange f)

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr R G Connor a) Name

b) Position/status Manufacturing & Supply

Initial notification/

amendment

Initial notification

President, Global

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

5493000HZTVUYLO1D793 b) LEI

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence

each ('Ordinary Shares')

ISIN: GB0009252882

b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12				
		July 2018.				
,		Price(s) Volume(s)				
c)	Price(s) and volume(s)	£15.7091 39.972				
d)	Aggregated information Aggregated volume Price	n/a (single transaction)				
e)	Date of the transaction	2018-07-12				
f)	Place of the transaction	London Stock Exchange (XLON)				
1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Mr L Debruyne				
b)	Position/status	President, Global Vaccines				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GlaxoSmithKline plc				
	LEI	5493000HZTVUYLO1D793				
	Details of the transaction(s): section to b	be repeated for (i) each type of				
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each					
	place where transaction(s) has been con					
		Ordinary shares of 25 pence each ('Ordinary Shares')				
a)	Description of the financial instrument	•				
,						
		Acquisition of Ordinary				
b)	Nature of the transaction	Shares following the				
D)	Nature of the transaction	re-investment of dividends paid to shareholders on 12				
		July 2018.				
۱ء	Drieg(s) and velvers(s)	Price(s) Volume(s)				
c)	Price(s) and volume(s)	£15.7091 1046.463				
d)	Aggregated information Aggregated volume Price	n/a (single transaction)				
e)	Date of the transaction	2018-07-12				
C)	Place of the transaction	London Stock Exchange				
f)		(XLON)				
		•				
1.	Details of PDMR/person closely associa	Mr S Dingemans				
a)	Name					
b)	Position/status Initial notification/	Chief Financial Officer				
c)	amendment	Initial notification				
2.						

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

re-investment of dividends b) Nature of the transaction

paid to shareholders on 12

July 2018.

Price(s) Volume(s) c) Price(s) and volume(s)

£15.7091 992.245

Aggregated information n/a (single transaction)

Aggregated volume Price

e) Date of the transaction 2018-07-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

SVP, Global Ethics and

b) Position/status Compliance

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

re-investment of dividends b) Nature of the transaction

paid to shareholders on 12

July 2018.

Price(s) Volume(s) c) Price(s) and volume(s)

292.397 £15.7091

d) Aggregated information n/a (single transaction)

Aggregated volume Price

each ('Ordinary Shares')

e) Date of the transaction 2018-07-12 Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D S Redfern b) Position/status Chief Strategy Officer Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') a) Description of the financial instrument ISIN: GB0009252882 **Acquisition of Ordinary** Shares following the re-investment of dividends b) Nature of the transaction paid to shareholders on 12 July 2018. Price(s) Volume(s) c) Price(s) and volume(s) £15.7091 1837.506 Aggregated information n/a (single transaction) Aggregated volume Price e) Date of the transaction 2018-07-12 Place of the transaction London Stock Exchange (XLON) 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms C Thomas b) Position/status SVP, Human Resources Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence

a) Description of the financial instrument ISIN: GB0009252882

	· ·	•					
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018.					
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7091 1165.071					
d)	Aggregated information Aggregated volume Price	n/a (single transaction)					
e)		2018-07-12					
f)	Place of the transaction	London Stock Exchange (XLON)					
1.	1 ,						
a)		Mr P C Thomson President, Global Affairs					
b)	Position/status	Trestaent, Global Allans					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882					
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018.					
c)	Price(s) and volume(s)	Price(s) Volume(s)					
d)	Aggregated information	£15.7091 971.581 n/a (single transaction)					
e)	Aggregated volume Price Date of the transaction	2018-07-12					
	Place of the transaction	London Stock Exchange					
f)		(XLON)					
1. a)	Details of PDMR/person closely associated with them ('PCA') Name Mrs K Thomson						
,	Position/status	PCA of Mr P C Thomson					
U)		(President, Global Affairs)					
c)	Initial notification/ amendment	Initial notification					
2							

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 12

July 2018.

c) Price(s) and volume(s) Price(s) Volume(s)

£15.7091 120.372

n/a (single transaction)

Aggregated information
 Aggregated volume Price

e) Date of the transaction 2018-07-12

Place of the transaction London Stock Exchange

(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: July 16, 2018

By: VICTORIA WHYTE

Victoria Whyte

Authorised Signatory for and on behalf of GlaxoSmithKline plc